Neupro(R) Filed With The FDA For The Treatment Of Advanced-Stage Parkinson’s Disease
UCB announced that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as adjunctive therapy with levodopa in adult patients with advanced-stage Parkinson’s disease has been accepted for filing by the U.S. Food and Drug Administration (FDA). [click link for full article]
More: continued here